WebMay 3, 2024 · PRIMARY OBJECTIVES: Phase II. To evaluate the impact of adding local consolidative therapy (LCT) to maintenance systemic therapy versus maintenance systemic therapy alone on progression-free survival for patients with metastatic non-small cell lung cancer (NSCLC) with no evidence of progression and limited metastatic sites after first … WebIn overall conclusion, the NETTER-1 study demonstrated that 177 Lu-DOTATATE yielded a clinically and statistically significant improvement in PFS as a primary endpoint (HR: …
Novartis 177Lu-PSMA-617 significantly improves overall survival and ...
Webtients. Overall 177Lu-PRLT was safe, with minimal adverse effects evident during follow-up in both T-pretreated and T-na¨ıve patients. Conclusion: 177Lu-PRLT is a promising therapy in mCRPC, with en-couraging outcomes and minimal associated toxicity seen in both our T-na¨ıve and heavily pretreated patient cohorts. WebFeb 27, 2024 · Despite not yielding a significant improvement in median overall survival (OS) among patients with advanced midgut neuroendocrine tumors, treatment with 177 … jiren teaches gohan
Why lutetium-177-PSMA treatment sometimes may not help, and …
WebBackground. Aumolertinib is a novel, irreversible third generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). APOLLO, a pivotal phase II single-arm study (NCT02981108), has demonstrated progression-free survival (PFS) benefit with a favorable safety profile in pretreated EGFR T790M positive NSCLC patients. WebDiscover the Kev\u0027s Quantocks; and other walking, running and cycling routes with OS Maps online mapping and route planning tools. WebDec 19, 2024 · Lu-177-PSMA usually improves survival We’ve seen in a couple of small trials in Germany and Australia that Lu-177-PSMA seemed to provide better than expected survival. In Germany, average (median) overall survival was 12.9 months across 104 patients. In Australia, average (median) overall survival was 13.3 months across 50 … jirgens civil pty ltd